Subsys sales almost triple for Insys


Insys Therapeutics (INSY +4.5%) Q2 results: Revenues: $55.7M (+196.3%); Operating Expenses: $34.0M (+209.1%); Net Income: $9.5M (+108.2%); EPS: $0.26 (+52.9%); Quick Assets: $54.7M (+19.4%).

Subsys (fentanyl sublingual spray) sales: $54.6M (+195.1%).

No financial guidance given.

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs